EGFR as a clinical marker in glioblastomas and other gliomas

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International Journal of Biological Markers

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.5301/ijbm.5000301PMID 28885661
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

  2016cited by this paper
• Trial Watch: Glioblastoma vaccine therapy disappointment in Phase III trial

  2016cited by this paper
• AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

  2015cited by this paper
• Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC)

  2014cited by this paper
• Epidermal growth factor receptor mutations in lung adenocarcinoma

  2014cited by this paper
• Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.

  2014cited by this paper
• Epidermal growth factor receptor and variant III targeted immunotherapy.

  2014cited by this paper
• Correlation of preoperative seizures with clinicopathological factors and prognosis in anaplastic gliomas: a report of 198 patients from China.

  2014cited by this paper
• Glioblastoma – A tale of two tumors: Case comparison and literature review

  2014cited by this paper
• Glioblastoma multiforme: State of the art and future therapeutics

  2014cited by this paper
• Predictive biomarkers investigated in glioblastoma

  2014cited by this paper
• Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges.

  2014cited by this paper
• Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy

  2014cited by this paper
• Molecular pathologic diagnosis of epidermal growth factor receptor.

  2014cited by this paper
• Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

  2013cited by this paper
• RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.

  2013cited by this paper
• Screening for EGFR Amplifications with a Novel Method and Their Significance for the Outcome of Glioblastoma Patients

  2013cited by this paper
• Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240

  2012cited by this paper
• Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

  2012cited by this paper
• EGFR Gene Variants Are Associated with Specific Somatic Aberrations in Glioma

  2012cited by this paper
• Prognostic Significance of EGFR Gene Amplification and Overexpression in Diffuse Astrocytomas—A Literature Study

  2012cited by this paper
• Nimotuzumab treatment of malignant gliomas

  2012cited by this paper
• Genetic Variation in the EGFR Gene and the Risk of Glioma in a Chinese Han Population

  2012cited by this paper
• The ERBB network: at last, cancer therapy meets systems biology

  2012cited by this paper
• Paradoxical Relationship Between the Degree of EGFR Amplification and Outcome in Glioblastomas

  2012cited by this paper
• Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas

  2012cited by this paper
• Epidermal Growth Factor Receptor Is Related to Poor Survival in Glioblastomas: Single-Institution Experience

  2012cited by this paper
• Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.

  2012cited by this paper
• Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

  2011cited by this paper
• Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial

  2011cited by this paper
• Epidermal growth factor receptor mutation in gastric cancer

  2011cited by this paper
• Autophagy and Akt promote survival in glioma

  2011cited by this paper
• Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

  2011cited by this paper
• Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

  2011cited by this paper
• Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity.

  2011cited by this paper
• Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain

  2011cited by this paper
• Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death

  2011cited by this paper
• Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.

  2011cited by this paper
• Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells

  2011cited by this paper
• Acquired MET Expression Confers Resistance to EGFR Inhibition In a Mouse Model of Glioblastoma Multiforme

  2011cited by this paper
• Expression of EGFRvIII in glioblastoma: prognostic significance revisited.

  2011cited by this paper
• Chromosome 7p11.2 (EGFR) variation influences glioma risk.

  2011cited by this paper
• Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis.

  2010cited by this paper
• Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.

  2010cited by this paper
• Cancer esearch cular and Cellular Pathobiology ermal Growth Factor Receptor Expression Identifies ctionally and Molecularly Distinct Tumor-Initiating Cells uman Glioblastoma Multiforme and Is Required R Gliomagenesis

  2010cited by this paper
• Genetic variations in EGF and EGFR and glioblastoma outcome

  2010cited by this paper
• A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

  2010cited by this paper
• Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.

  2010cited by this paper
• Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression.

  2010cited by this paper
• Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence

  2010cited by this paper
• Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma

  2010cited by this paper
• Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.

  2009cited by this paper
• Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.

  2009cited by this paper
• Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?

  2009cited by this paper
• A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

  2009cited by this paper
• The promises and pitfalls of RNA-interference-based therapeutics

  2009cited by this paper
• EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.

  2009cited by this paper
• Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

  2009cited by this paper
• Clinical and immunohistochemical prognostic factors in adult glioblastoma patients.

  2009cited by this paper
• Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

  2009cited by this paper
• Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

  2009cited by this paper
• Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments

  2008cited by this paper
• Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers

  2008cited by this paper
• Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor.

  2008cited by this paper
• Malignant gliomas in adults.

  2008cited by this paper
• microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma.

  2008cited by this paper
• Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples

  2008cited by this paper
• Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

  2008cited by this paper
• Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

  2007cited by this paper
• Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker

  2007cited by this paper
• Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

  2007cited by this paper
• Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach

  2007cited by this paper
• ErbB receptors: from oncogenes to targeted cancer therapies.

  2007cited by this paper
• Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

  2007cited by this paper
• Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies

  2007cited by this paper
• The Efficacy of Epidermal Growth Factor Receptor–Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization

  2007cited by this paper
• Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target

  2006cited by this paper
• Supratentorial glioblastoma in adults: Identification of subsets and their clinical correlation

  2006cited by this paper
• Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo

  2006cited by this paper
• Activation of STAT3, MAPK, and AKT in Malignant Astrocytic Gliomas: Correlation With EGFR Status, Tumor Grade, and Survival

  2006cited by this paper
• Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

  2006cited by this paper
• Prognostic impact of molecular markers in a series of 220 primary glioblastomas

  2006cited by this paper
• The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis.

  2006cited by this paper
• Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival.

  2006cited by this paper
• EGFR amplification and lack of activating mutations in metaplastic breast carcinomas

  2006cited by this paper
• Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines.

  2006cited by this paper
• Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival

  2006cited by this paper
• EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

  2005cited by this paper
• Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01

  2005cited by this paper
• Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis

  2005cited by this paper
• Magnetic Resonance Imaging Characteristics Predict Epidermal Growth Factor Receptor Amplification Status in Glioblastoma

  2005cited by this paper
• Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas

  2005cited by this paper
• Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients

  2005cited by this paper
• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  2005cited by this paper
• The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years

  2005cited by this paper
• A comprehensive pathway map of epidermal growth factor receptor signaling

  2005cited by this paper
• Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

  2005cited by this paper
• Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group.

  2005cited by this paper

• Machine Learning–Based Preoperative Predicting TERT Promoter Mutation and EGFR Gene Amplification Phenotype in IDH Wild-Type Glioblastoma Using Advanced MR Habitat Imaging

  2026cites this paper
• Nanostructured lipid carriers for enhanced batimastat delivery across the blood–brain barrier: an in vitro study for glioblastoma treatment

  2025cites this paper
• scEVE: a single-cell RNA-seq ensemble clustering algorithm capitalizing on the differences of predictions between multiple clustering methods

  2025cites this paper
• Mechanotransduction as a therapeutic target for brain tumours

  2025cites this paper
• Molecular drivers in primary brain tumor formation.

  2025cites this paper
• A novel 5-protein kinase risk signature for predicting glioma prognosis and immunotherapy responsiveness

  2025cites this paper
• Advances and Challenges in Nano-Delivery Systems for Glioblastoma Treatment: A Comprehensive Review

  2025cites this paper
• Graphene quantum dot-integrated nanocomposites: a promising avenue for glioblastoma treatment

  2025cites this paper
• Tailoring imaging probes for defining glioma invasive margins: Tracing the molecular footprints of cancer cells.

  2025cites this paper
• Escaping from Flatland: 3D Carborane-Based Bioisosteres of Erlotinib as Potential Anticancer Agents

  2025cites this paper
• Spatial transcriptomics of glioblastoma defines biologically and clinically significant reprogramming patterns across unique spatial microenvironments

  2025cites this paper
• Recombination between fragile regions associated with chromosomal rearrangements in glioblastoma can be mediated by RAGs

  2025cites this paper
• Therapeutic Reprogramming of Glioblastoma Phenotypic States Using Multifunctional Heparin Nanoparticles

  2025cites this paper
• Integrative multi-omics analysis identifies TGFA as a novel glioma susceptibility gene and therapeutic target

  2025cites this paper
• BIOLOGICAL EFFECTS OF CURCUMINOIDS AND HOMOLEPTIC METAL COMPLEXES OF CURCUMINOIDS AGAINST NON-TUMORAL ASTROCYTIC AND GLIOBLASTOMA CELL LINES

  2025cites this paper
• The Aptamer bi-(AID-1-T) Synergizes with Radiation to Inhibit Proliferation of Human Glioma Cells

  2025cites this paper
• Tight junction proteins in glial tumors development and progression

  2025cites this paper
• Design, Synthesis, and Anti‐Glioma Activity Evaluation of Dehydroabietic Acid Derivatives

  2025cites this paper
• Deciphering the Effect of Phytocompounds In Vitro and Mechanism Using Bioinformatic Tools in Glioblastoma

  2025cites this paper
• Discovering potential therapeutic targets in glioblastoma multiforme using a multi-omics approach.

  2025cites this paper
• Pyrazole derivatives as dual COX-2/EGFR inhibitors with anticancer potential: Optimization of difenamizole Analogs.

  2025cites this paper
• Integrative Transcriptomic and Perturbagen Analyses Reveal Sex-Specific Molecular Signatures Across Glioma Subtypes

  2025cites this paper
• Detection of genetic alterations via molecular cytogenetic analyses in a case series of pediatric glioma patients in Colombia: a pilot study

  2025cites this paper
• Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel

  2025cites this paper
• Overcoming barriers and shaping the future: Challenges and innovations in nucleic acid therapies for Glioblastoma.

  2025cites this paper
• Innovative radiotherapies for the treatment of glioblastoma

  2025cites this paper
• Potential therapeutic targets of Aquilaria malaccensis leaf extract: A network pharmacology approach

  2025cites this paper
• The Prognostic Significance of Epidermal Growth Factor Receptor Amplification and Epidermal Growth Factor Receptor Variant III Mutation in Glioblastoma: A Systematic Review and Meta-Analysis with Implications for Targeted Therapy

  2025cites this paper
• Mechanistic Insights into the Anti-Glioma Effects of Exosome-Like Nanoparticles Derived from Garcinia Mangostana L.: A Metabolomics, Network Pharmacology, and Experimental Study

  2025cites this paper
• Scutellarin combined with lidocaine exerts antineoplastic effect in human glioma associated with repression of epidermal growth factor receptor signaling

  2025cites this paper
• Advancing Glioblastoma Prognosis: A Review of Machine Learning, Radiomics, and Multi-Omics Integration for Survival Prediction and Subtyping

  2025cites this paper
• Identification of Key Biomarkers Associated with Glioma Hemorrhage: Evidence from Bioinformatic Analysis and Clinical Validation

  2025cites this paper
• Molecular markers in Gliomas: A practical review and algorithm proposal

  2025cites this paper
• Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status

  2024cites this paper
• Proline Metabolism in WHO G4 Gliomas Is Altered as Compared to Unaffected Brain Tissue

  2024cites this paper
• TRIM56: a promising prognostic immune biomarker for glioma revealed by pan-cancer and single-cell analysis

  2024cites this paper
• EphB3 receptor suppressor invasion, migration and proliferation in glioma by inhibiting EGFR-PI3K/AKT signaling pathway.

  2024cites this paper
• TGIF2 is a potential biomarker for diagnosis and prognosis of glioma

  2024cites this paper
• DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma

  2024cites this paper
• The generation of glioma organoids and the comparison of two culture methods

  2024cites this paper
• N6‐isopentenyladenosine inhibits aerobic glycolysis in glioblastoma cells by targeting PKM2 expression and activity

  2024cites this paper
• Molecular characterization and survival analysis of a cohort of glioblastoma, IDH-wildtype.

  2024cites this paper
• Discovery and Optimization of N-Arylated Tetracyclic Dicarboximides That Target Primary Glioma Stem-like Cells.

  2024cites this paper
• Human Melanoma and Glioblastoma Cells Express Cathepsins Supporting Reovirus Moscow Strain Infection

  2024cites this paper
• Predictive and Prognostic Significance of Molecular Biomarkers in Glioblastoma

  2024cites this paper
• Glioblastoma therapy: State of the field and future prospects.

  2024cites this paper
• Family Malvaceae: a potential source of secondary metabolites with chemopreventive and anticancer activities supported with in silico pharmacokinetic and pharmacodynamic profiles

  2024cites this paper
• Structural alterations of the EGFR gene in glioblastoma samples as a prognostic factor and molecular target for therapy

  2024cites this paper
• A DTI-based radiomics model for predicting epidermal growth factor receptor (EGFR) amplification in adult IDH1-wild glioblastomas

  2024cites this paper
• The mutated in colorectal cancer (MCC) gene can serve as a potential biomarker of glioblastoma

  2024influential citation
• New frontiers in domain-inspired radiomics and radiogenomics: increasing role of molecular diagnostics in CNS tumor classification and grading following WHO CNS-5 updates

  2024cites this paper
• Advances in Neuroinflammation

  2024cites this paper
• Molecular Profile as an Outcome Predictor in Glioblastoma along with MRI Features and Surgical Resection: A Scoping Review

  2024cites this paper
• Phenotypic and Genetic Heterogeneity of Glioblastoma: Comparison of MRI and PET/CT Parameters with the Molecular Genetic Characteristics of Tumors

  2024cites this paper
• Molecular Determinants for Photodynamic Therapy Resistance and Improved Photosensitizer Delivery in Glioma

  2024cites this paper
• Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges

  2024cites this paper
• Glioblastoma phenotypic and genetic heterogeneity, comparison of MRI and PET/CT parameters with tumor molecular genetic characteristics

  2024cites this paper
• TSPAN4 influences glioblastoma progression through regulating EGFR stability

  2024cites this paper
• TGF-β signaling: critical nexus of fibrogenesis and cancer

  2024cites this paper
• Metabolic Insight into Glioma Heterogeneity: Mapping Whole Exome Sequencing to In Vivo Imaging with Stereotactic Localization and Deep Learning

  2024cites this paper
• Exploring the Difference between Newly Diagnosed and Recurrent Glioblastoma by Screening a Constant Tumor Cell Type via Single-Cell Sequencing

  2024cites this paper
• Expression pattern of phosphatase and tensin homolog and epidermal growth factor receptor in patients with brain tumor

  2023cites this paper
• Exploring Scutellaria baicalensis bioactives as EGFR tyrosine kinase inhibitors: Cheminformatics and molecular docking studies

  2023cites this paper
• The Crosstalk between the EGFR and IFN-γ Pathways and Synergistic Roles in Survival Prediction and Immune Escape in Gliomas

  2023cites this paper
• Mechanisms Involved in the Therapeutic Effect of Cannabinoid Compounds on Gliomas: A Review with Experimental Approach.

  2023cites this paper
• Multi-Target Neural Differentiation (MTND) Therapeutic Cocktail to Suppress Brain Tumor

  2023cites this paper
• Identifying Personalised treatment plan for GBM using Multidimensional Patient Similarity Analytics

  2023cites this paper
• Functionalized nanoparticles crossing the brain–blood barrier to target glioma cells

  2023cites this paper
• Understanding the molecular profiling of diffuse gliomas classification: A brief overview

  2023cites this paper
• Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?

  2023cites this paper
• NUDT21 alters glioma migration through differential alternative polyadenylation of LAMC1

  2023influential citation
• A receptor-mediated landscape of druggable and targeted nanomaterials for gliomas

  2023cites this paper
• Pre-diagnostic blood biomarkers for adult glioma

  2023cites this paper
• Zinc Finger E-Box Binding Homeobox Family: Non-Coding RNA and Epigenetic Regulation in Gliomas

  2023cites this paper
• Machine learning applications on intratumoral heterogeneity in glioblastoma using single-cell RNA sequencing data.

  2023cites this paper
• Effect of tumor genetics, pathology, and location on fMRI of language reorganization in brain tumor patients

  2023cites this paper
• Long non-coding RNA in glioblastoma invasion: Angiogenesis and mesenchymal transition via PI3K and Wnt signalling

  2023cites this paper
• Constructing metabolism-protein interaction relationship to identify glioma prognosis using deep learning

  2023cites this paper
• Advances in antibody-based drugs and their delivery through the blood-brain barrier for targeted therapy and immunotherapy of gliomas.

  2023cites this paper
• MultiSimNeNc: A network representation learning-based module identification method by network embedding and clustering

  2023cites this paper
• Impact of GAP-43, Cx43 and actin expression on the outcome and overall survival in diffuse and anaplastic gliomas

  2023cites this paper
• Spastin Promotes the Migration and Invasion Capability of T98G Glioblastoma Cells by Interacting with Pin1 through Its Microtubule-Binding Domain

  2023cites this paper
• The Role of Cellular Prion Protein in Glioma Tumorigenesis Could Be through the Autophagic Mechanisms: A Narrative Review

  2023cites this paper
• Characterization of a lactate metabolism-related signature for evaluation of immune features and prediction prognosis in glioma

  2023cites this paper
• EGFR-Targeted Cellular Delivery of Therapeutic Nucleic Acids Mediated by Boron Clusters

  2022cites this paper
• MiR-3918 Inhibits Tumorigenesis of Glioma via Targeting EGFR to Regulate PI3K/AKT and ERK Pathways

  2022cites this paper
• Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma

  2022cites this paper
• Visualizing surface marker expression and intratumoral heterogeneity with SERRS-NPs imaging

  2022cites this paper
• Identification of an IL-4-Related Gene Risk Signature for Malignancy, Prognosis and Immune Phenotype Prediction in Glioma

  2022cites this paper
• Inhibiting CK2 among Promising Therapeutic Strategies for Gliomas and Several Other Neoplasms

  2022cites this paper
• The prognostic significance of further genotyping H3G34 diffuse hemispheric gliomas

  2022cites this paper
• Characterization of aging tumor microenvironment with drawing implications in predicting the prognosis and immunotherapy response in low-grade gliomas

  2022cites this paper
• Differences in the Expression Patterns of TGFβ Isoforms and Associated Genes in Astrocytic Brain Tumors

  2022cites this paper
• Recognition of a Novel Gene Signature for Human Glioblastoma

  2022cites this paper
• Proline Metabolism in Malignant Gliomas: A Systematic Literature Review

  2022cites this paper
• Signaling Pathways Regulating the Expression of the Glioblastoma Invasion Factor TENM1

  2022cites this paper
• The progress of multimodal imaging combination and subregion based radiomics research of cancers

  2022cites this paper
• The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions

  2022cites this paper
• A Targeted Next-Generation Sequencing Panel to Genotype Gliomas

  2022cites this paper
• Gliomas molecular markers: importance in treatment, prognosis and applicability in brazilian health system.

  2022influential citation